Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Palmitoyl-Carnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17667555 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Hydrochloric Acid SCHEMBL8620445 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Hydrochloric Acid SCHEMBL8580303 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Hydrochloric Acid SCHEMBL1321243 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Hydrochloric Acid SCHEMBL8580295 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Octanoylcarnitine SCHEMBL16535179 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Hydrochloric Acid SCHEMBL8620442 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Hydrochloric Acid SCHEMBL8620437 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Palmitoyl-Carnitine SCHEMBL20580076 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Palmitoyl-Carnitine SCHEMBL515545 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302912-A1 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-02 | — | — | US | disclosed |
| EP-4609875-A2 | COMPOSITION CONTAINING PEPTIDE COMPOUND AND SURFACTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-03 | — | — | EP | disclosed |
| EP-4166133-B1 | COMPOSITION CONTAINING PEPTIDE COMPOUND AND SURFACTANT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-20250186542-A1 | COMPOSITION CONTAINING PEPTIDE COMPOUND FOR USE WITH SURFACTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-12 | — | — | US | disclosed |
| EP-4406546-A1 | COMPOSITION CONTAINING PEPTIDE COMPOUND FOR USE WITH SURFACTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-07-31 | — | — | EP | disclosed |
| CN-118354782-A | Compositions comprising peptide compounds for use in combination with surfactants | 中外制药株式会社 | 2024-07-16 | — | — | CN | disclosed |
| CN-118176012-A | Compositions comprising a peptide compound and a surfactant | 中外制药株式会社 | 2024-06-11 | — | — | CN | disclosed |
| CN-112851747-B | Method for synthesizing polypeptide modified by quaternary ammonium base derivative | 深圳翰宇药业股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| WO-2023214509-A1 | COMPOSITION CONTAINING PEPTIDE COMPOUND FOR USE WITH SURFACTANT | 中外製薬株式会社 | 2023-11-09 | — | — | WO | disclosed |
| WO-2023063376-A1 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | 中外製薬株式会社 | 2023-04-20 | — | — | WO | disclosed |
| EP-4166133-A1 | COMPOSITION CONTAINING PEPTIDE COMPOUND AND SURFACTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-04-19 | — | — | EP | disclosed |
| US-8614343-B2 | Process for the production of a fatty acid/carnitine derivative | LONZA LTD. (CH) | 2013-12-24 | — | — | US | disclosed |
| EP-2393774-B1 | PROCESS FOR THE PRODUCTION OF A FATTY ACID/L-CARNITINE DERIVATIVE | LONZA AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| EP-2393774-A1 | PROCESS FOR THE PRODUCTION OF A FATTY ACID/L-CARNITINE DERIVATIVE | Lonza Ltd (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-20110295026-A1 | PROCESS FOR THE PRODUCTION OF A FATTY ACID/CARNITINE DERIVATIVE | LONZA LTD. (CH) | 2011-12-01 | — | — | US | disclosed |
| WO-2010089094-A1 | PROCESS FOR THE PRODUCTION OF A FATTY ACID/L-CARNITINE DERIVATIVE | LONZA LTD (CH) | 2010-08-12 | — | — | WO | disclosed |
| EP-2216321-A1 | Process for the production of a fatty acid/carnitine derivative | Lonza Ltd. (CH) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186542-A1 | COMPOSITION CONTAINING PEPTIDE COMPOUND FOR USE WITH SURFACTANT | PCTP, CETP, PLTP | MAPK1 3880/4885MAPT 3361/4885LMNA 1666/4885 |
| US-20250302912-A1 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | PCTP, CETP, PLTP | MAPK1 2130/4885MAPT 1763/4885LMNA 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.